GS3 007
Alternative Names: GS3-007; GS3-007ALatest Information Update: 04 Oct 2026
At a glance
- Originator GeneScience Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Somatotropin deficiency
Most Recent Events
- 18 Jan 2026 Phase-I/II clinical trials in Somatotropin deficiency (In adolescents, In children, In adults, In the elderly) in China (PO) (NCT07264595)
- 07 Jan 2026 GS3 007 is still in phase I clinical trials in Somatotropin deficiency (In volunteers) in China (PO, Liquid) (NCT05611281)
- 07 Jan 2026 Changchun GeneScience Pharmaceutical initiates phase I clinical trials in healthy volunteers in China (PO, Suspension) (NCT07473570)